Chong-XianPanMD

Oncology • West Roxbury, MA

Associate Professor, Internal Medicine, UC, Davis School of Medicine

Join to view full profile

Are you Dr. Pan?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1400 Vfw Pkwy
West Roxbury, MA 02132
Phone+1 857-203-6189

Summary

Dr. Chong-Xian Pan, MD is an oncologist in West Roxbury, Massachusetts. He is currently licensed to practice medicine in Massachusetts, California, and Illinois. He is affiliated with Boston Medical Center and is an Associate Professor at UC.

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 1999 - 2002
Shanghai Medical UniversityClass of 1989

Certifications & Licensure

MA State Medical License 2020 - 2025
CA State Medical License 2005 - 2020
IL State Medical License 1999 - 2002
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer Start of enrollment: 2010 Dec 01
Terminated
Early Phase 1
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Unknown status
Phase 1, Phase 2
Oxaliplatin in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2015 May 01
Completed
Early Phase 1
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2017 Jan 17
Recruiting
Phase 1, Phase 2
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2017 Jan 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.
Brian S White, Xing Yi Woo, Soner Koc, Todd Sheridan, Steven B Neuhauser
Cancer Research. 2024-07-02
3 citations
Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques.
Mohamed A Abd El-Salam, Maria J Troulis, Chong-Xian Pan, Rema A Rao
Cancer Cytopathology. 2024-02-01
8 citations
A transformable nanoplatform with multiple therapeutic and immunostimulatory properties for treatment of advanced cancers.
Xiangdong Xue, Haijing Qu, Ruonan Bo, Dalin Zhang, Zheng Zhu
Biomaterials. 2023-08-01

Press Mentions

Bladder Cancer: Know the SignsJune 15th, 2021